Hengrui Medicine (600276.SH): Three drugs including apatinib hydrochloride tablets have been approved to conduct clinical trials.

Zhtng Cijng APP News, Hengrui Medicine (600276.SH) announced that recently, the company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have received approval from the National Medical Products Administration regarding the issuance of the "Drug Clinical Trial Approval Notice" for SHR-8068 injection, Atezolizumab injection, and Apatinib mesylate tablets. Clinical trials will be carried out in the near future.